Stanford's SPARK hosts ideas so 'crazy' they just might work

Stanford University School of Medicine tells the tale of one researcher's desire to move her research into better heart disease drugs out of the lab and into the clinic--a quest that, she learned the hard way, turned out to be naive as doors were politely slammed in her face. So, Daria Mochly-Rosen decided to take matters into her own hands. And that was the spark for SPARK, Stanford's bioscience incubator, founded 5 years ago to nurture "crazy ideas" that pharmaceutical companies won't touch. Feature

Suggested Articles

GigaGen joined a group of companies making plasma-based, polyclonal antibody treatments for COVID-19.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Selectively targeting TGF-beta1 with Scholar Rock's SRK-181 overcame primary resistance to checkpoint inhibitor therapy in mice.